Nasdaq Copenhagen
Every company in the roster listed on Nasdaq Copenhagen.
Every company in the roster listed on Nasdaq Copenhagen.
4 of 4 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
ALK-AbellóALK B · Nasdaq Copenhagen | 1 asset: 1 approved | Approved assets only | Apr 2027Epinephrine · Approved | — | — | — | — |
GubraGUBRA · Nasdaq Copenhagen | 2 assets: 2 Ph 2 | BI 3034701Phase 2 · ObesityWeak signal | 15 Dec 2026BI 3034701 · Phase 1 | — | — | — | — |
H. LundbeckHLUN.B · Nasdaq Copenhagen | 10 assets: 8 approved, 1 Ph 3, 1 Ph 2 | BexicaserinPhase 3 · EpilepsyPartial signal | 31 Dec 2026Bexicaserin · Phase 3 | — | — | — | — |
Zealand PharmaZEAL · Nasdaq Copenhagen | 6 assets: 2 approved, 2 Ph 3, 1 Ph 2, 1 Ph 1 | survodutidePhase 3 · ObesityReliable signal | 8 Dec 2026survodutide · Phase 1 | — | $2.2BMar 2026 | — | ~$224M |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.